When Donald Trump first announced sweeping 100% tariffs on imported pharmaceutical drugs, his supporters applauded what sounded like a populist move. Trump claimed it was about putting “America First,” standing up to foreign companies, and lowering costs for U.S. patients. But just five days later, the mask slipped.
Trump unveiled TrumpRx, a new venture to sell prescription drugs directly to consumers – complete with a sweetheart deal that exempted Pfizer, one of the largest pharmaceutical companies in the world, from those very tariffs for the next three years.
The message couldn’t be clearer: while competitors faced crippling tariffs, Pfizer got a free pass – and Trump positioned himself to profit.
Top Three Takeaways from the Article:
Tariffs as a setup for profit – Trump announced steep 100% tariffs on imported pharmaceuticals, only to carve out a path for his own drug venture, TrumpRx, days later.
Special treatment for Pfizer – TrumpRx struck a deal with Pfizer that exempted the company from those tariffs for three years, highlighting blatant favoritism and self-dealing.
Corruption over public interest – The scheme shows how Trump leverages policy not to lower drug prices for Americans, but to enrich himself and his business allies at the expense of consumers.
A Tariff That Isn’t What It Seems
At first glance, a 100% tariff sounds like it would punish foreign drug makers. But in reality, tariffs are taxes paid by American consumers. If companies had to import drugs at double the price, it wouldn’t be Big Pharma footing the bill – it would be patients at the pharmacy counter.
That’s what makes the Pfizer exemption so troubling. Not only did Trump single out one favored company for protection, he tied that exemption to a new personal venture – TrumpRx – that could now dominate the drug retail market under artificial conditions Trump himself created.
This isn’t about “beating China” or “bringing jobs back.” It’s about rigging the market so one company, and one politician-turned-businessman, gets richer while the rest of us pay more.
If this all feels familiar, it should. Trump has a long history of turning public office into personal profit:
- The Trump International Hotel in D.C. became a hub for lobbyists, foreign dignitaries, and corporations who wanted to curry favor with the president.
- His golf resorts saw a surge of membership fees and foreign business while he was in office.
- Trump University promised opportunity but delivered lawsuits, refunds, and fraud findings.
TrumpRx is cut from the same cloth. What looks like “policy” is really just another hustle, engineered to enrich Trump and his allies while spinning it as patriotism.
Pfizer’s Special Treatment
The Pfizer deal is especially galling because Trump has long railed against Big Pharma. Yet here, one of the largest drug companies on earth gets preferential treatment – while competitors are punished.
Why Pfizer? The details of their arrangement remain murky, but the exemption looks suspiciously like a political payoff dressed up as policy. Trump’s allies have already suggested that TrumpRx could use Pfizer’s products as a core part of its consumer offerings, giving the company a direct line into a new marketplace that only exists because Trump kneecapped its rivals.
The real losers in this arrangement are ordinary Americans. Patients will face higher drug prices as a result of tariffs on imports, while TrumpRx and Pfizer profit. And with fewer competitors able to afford access to the U.S. market, drug choice could shrink, further driving up costs.
Meanwhile, Trump gets to claim victory in a fight he manufactured – blaming foreigners for high drug costs while quietly making deals to cash in on the chaos.
The Grift Continues
TrumpRx is not about lowering costs, protecting Americans, or reforming healthcare. It’s about Trump using political power to rig markets for his own benefit, with Pfizer playing along as a willing partner.
In the end, Trump’s slogan could use a rewrite: not America First, but Trump First – and everyone else pays the price.